Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Arcturus Therapeutics Holdings Inc
(NQ:
ARCT
)
27.26
+0.47 (+1.75%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Arcturus Therapeutics Holdings Inc
< Previous
1
2
3
Next >
Arcturus Therapeutics Reports New Data and Provides Additional Updates from ARCT-154 and ARCT-165 Clinical Trials
December 16, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics Appoints Jing Marantz, M.D., Ph.D., M.B.A. to its Board of Directors
December 13, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference
November 22, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 18, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics Announces Third Quarter 2021 Financial Update and Pipeline Progress
November 08, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on November 8, 2021
October 25, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics Announces Leadership Appointments
October 21, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 20, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
October 12, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration
September 22, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
September 22, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021
September 08, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
September 07, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics Announces Second Quarter 2021 Financial Results and mRNA Vaccine and Therapeutics Pipeline Progress
August 09, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165, Next Generation STARR™ mRNA Vaccines Targeting SARS-CoV-2 Variants of Concern, in a Phase 1/2 Study
August 03, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Announces Approval of a Clinical Trial Application to Advance ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting the SARS-CoV-2 Delta Variant and Other Variants of Concern
August 02, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics Collaborates with Vingroup to Establish Manufacturing Facility in Vietnam for Arcturus’ Investigational mRNA Vaccines for COVID-19
August 02, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Announces Regulatory Approval to Proceed with Phase 2 Study of ARCT-810 mRNA Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency
July 28, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 9, 2021
July 26, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
July 06, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
June 09, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics Announces First Quarter 2021 Company Overview and Financial Results and Provides New Clinical Data
May 10, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics to Report First Quarter 2021 Financial Results and Provide Corporate Update on May 10, 2021
May 03, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.